Megumi Murakami

Dr. Megumi Murakami

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
Andaleeb SajidAndaleeb Sajid
Andaleeb Sajid
SLSabrina Lusvarghi
Sabrina Lusvarghi
MMMegumi Murakami
Megumi Murakami
ECEduardo E. Chufan
Eduardo E. Chufan
BABiebele Abel
Biebele Abel
SASuresh V. Ambudkar
Suresh V. Ambudkar
Significance: The multidrug transporter P-glycoprotein protects tissues from xenobiotics and other toxic compounds by pumping them out of cells. This transporter has been implicated in altering the bioavailability of chemotherapeutic drugs and in the development of multidrug resistance in tumor cells. Despite decades of research, the modulation of P-glycoprotein to overcome drug resistance in the clinic has not been successful. Here, by substituting a group of 14 conserved residues in homologous transmembrane helices 6 and 12 with alanine, we generated a mutant that exhibits a change in the direction of transport from export to import for certain drug substrates including the taxol derivative flutax-1. The ability to convert P-glycoprotein into a drug importer provides a strategy to combat cancer drug resistance.

1 October 2018 in Cancer Letters
Verified
Journal Article
Closed access
Chung-Pu WuChung-Pu Wu
Chung-Pu Wu
MMMegumi Murakami
Megumi Murakami
SHSung-Han Hsiao
Sung-Han Hsiao
TLTe-Chun Liu
Te-Chun Liu
NYNi Yeh
Ni Yeh
SASuresh V. Ambudkar
Suresh V. Ambudkar

Verified
Journal Article
Open access
PDF file
Chung-Pu WuChung-Pu Wu
Chung-Pu Wu
YLYen-Ching Li
Yen-Ching Li
MMMegumi Murakami
Megumi Murakami
SHSung-Han Hsiao
Sung-Han Hsiao
YLYun-Chieh Lee
Yun-Chieh Lee
SASuresh V. Ambudkar
Suresh V. Ambudkar
ATP-binding cassette transporters, including ABCB1 (P-glycoprotein) and ABCG2 (BCRP/MXR/ABCP), are pivotal in multidrug resistance (MDR) development in cancer patients undergoing conventional chemotherapy. The absence of approved therapeutic agents for multidrug-resistant cancers presents a significant challenge in effectively treating cancer. Researchers propose repurposing existing drugs to sensitize multidrug-resistant cancer cells, which overexpress ABCB1 or ABCG2, to conventional anticancer drugs. The goal of this study is to assess whether furmonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor overcomes drug resistance mediated by ABCB1 and ABCG2 transporters. Furmonertinib stands out due to its ability to inhibit drug transport without affecting protein expression. The discovery of this characteristic was validated through ATPase assays, which revealed interactions between furmonertinib and ABCB1/ABCG2. Additionally, in silico docking of furmonertinib offered insights into potential interaction sites within the drug-binding pockets of ABCB1 and ABCG2, providing a better understanding of the underlying mechanisms responsible for the reversal of MDR by this repurposed drug. Given the encouraging results, we propose that furmonertinib should be explored as a potential candidate for combination therapy in patients with tumors that have high levels of ABCB1 and/or ABCG2. This combination therapy holds the potential to enhance the effectiveness of conventional anticancer drugs and presents a promising strategy for overcoming MDR in cancer treatment.

30 March 2023 in Cells
Verified
Journal Article
Open access
PDF file
Chung-Pu WuChung-Pu Wu
Chung-Pu Wu
CHCheng-Yu Hung
Cheng-Yu Hung
YHYa-Ju Hsieh
Ya-Ju Hsieh
MMMegumi Murakami
Megumi Murakami
YHYang-Hui Huang
Yang-Hui Huang
SASuresh V. Ambudkar
Suresh V. Ambudkar
Constitutive activation of the phosphoinositide-3-kinase (PI3K)/Akt signaling pathway is crucial for tumor growth and progression. As such, this pathway has been an enticing target for drug discovery. Although HS-173 is a potent PI3K inhibitor that halts cancer cell proliferation via G2/M cell cycle arrest, the resistance mechanisms to HS-173 have not been investigated. In this study, we investigated the susceptibility of HS-173 to efflux mediated by the multidrug efflux transporters ABCB1 and ABCG2, which are two of the most well-known ATP-binding cassette (ABC) transporters associated with the development of cancer multidrug resistance (MDR). We found that the overexpression of ABCB1 or ABCG2 significantly reduced the efficacy of HS-173 in human cancer cells. Our data show that the intracellular accumulation of HS-173 was substantially reduced by ABCB1 and ABCG2, affecting G2/M arrest and apoptosis induced by HS-173. More importantly, the efficacy of HS-173 in multidrug-resistant cancer cells could be recovered by inhibiting the drug-efflux function of ABCB1 and ABCG2. Taken together, our study has demonstrated that HS-173 is a substrate for both ABCB1 and ABCG2, resulting in decreased intracellular concentration of this drug, which may have implications for its clinical use.

9 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Chung-Pu WuChung-Pu Wu
Chung-Pu Wu
CHCheng-Yu Hung
Cheng-Yu Hung
MMMegumi Murakami
Megumi Murakami
YWYu-shan Wu
Yu-shan Wu
CLChun-Ling Lin
Chun-Ling Lin
SASuresh V. Ambudkar
Suresh V. Ambudkar
Ensartinib (X-396) is a promising second-generation small-molecule inhibitor of anaplastic lymphoma kinase (ALK) that was developed for the treatment of ALK-positive non-small-cell lung cancer. Preclinical and clinical trial results for ensartinib showed superior efficacy and a favorable safety profile compared to the first-generation ALK inhibitors that have been approved by the U.S. Food and Drug Administration. Although the potential mechanisms of acquired resistance to ensartinib have not been reported, the inevitable emergence of resistance to ensartinib may limit its therapeutic application in cancer. In this work, we investigated the interaction of ensartinib with P-glycoprotein (P-gp) and ABCG2, two ATP-binding cassette (ABC) multidrug efflux transporters that are commonly associated with the development of multidrug resistance in cancer cells. Our results revealed that P-gp overexpression, but not expression of ABCG2, was associated with reduced cancer cell susceptibility to ensartinib. P-gp directly decreased the intracellular accumulation of ensartinib, and consequently reduced apoptosis and cytotoxicity induced by this drug. The cytotoxicity of ensartinib could be significantly reversed by treatment with the P-gp inhibitor tariquidar. In conclusion, we report that ensartinib is a substrate of P-gp, and provide evidence that this transporter plays a role in the development of ensartinib resistance. Further investigation is needed.

30 January 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
CCChaoyun Cai
Chaoyun Cai
QTQiuxu Teng
Qiuxu Teng
MMMegumi Murakami
Megumi Murakami
SASuresh V. Ambudkar
Suresh V. Ambudkar
Zhe-Sheng ChenZhe-Sheng Chen
Zhe-Sheng Chen
VKVijaya L. Korlipara
Vijaya L. Korlipara
A series of twenty-two quinazolinamine derivatives showing potent inhibitory activities on breast cancer resistance protein (BCRP) and p-glycoprotein (P-gp) were synthesized. A cyclopropyl-containing quinazolinamine 22 was identified as a dual BCRP and P-gp inhibitor, while azide-containing quinazolinamine 33 showed BCRP inhibitory activity. These lead compounds were further investigated in a battery of mechanistic experiments. Compound 22 changed the localization of BCRP and P-gp in cells, thus inhibiting the efflux of anticancer drugs by the two ATP-binding cassette (ABC) transporters. In addition, both 22 and 33 significantly stimulated the ATP hydrolysis of the BCRP transporter, indicating that they can be competitive substrates of the BCRP transporter, and thereby increase the accumulation of mitoxantrone in BCRP-overexpressing H460/MX20 cells. Azide derivative 33, exhibited a greater inhibitory effect on BCRP after UV activation and can serve as a valuable probe for investigating the interactions of quinazolinamine derivatives with BCRP. Notably, the dual BCRP and P-gp inhibitors 4–5, 22–24, 27, and BCRP inhibitor 33 showed improved metabolic stability compared to Ko143.